Literature DB >> 7901809

Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis.

H P Hartung1, M Michels, K Reiners, P Seeldrayers, J J Archelos, K V Toyka.   

Abstract

Intercellular adhesion molecule ICAM-1 has a crucial role in the induction of an immune response and is instrumental in migration of T cells into inflamed tissue. We studied soluble ICAM-1 concentrations in patients with multiple sclerosis (MS), viral encephalitis, and other immunologic diseases, and compared results with those in other noninflammatory, nondemyelinating neurologic disorders as well as in healthy controls. MS patients with clinically active disease or enhancing lesions on MRI had elevated serum levels of soluble ICAM-1. Concentrations of soluble ICAM-1 were also increased in some patients with viral encephalitis. These findings raise the possibility that circulating ICAM-1 serves as a marker of acute inflammatory events in the brain and add to evidence implicating this adhesion molecule in the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901809     DOI: 10.1212/wnl.43.11.2331

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Soluble ICAM-1 serum levels in patients with intermediate uveitis.

Authors:  A M Klok; L Luyendijk; M J Zaal; A Rothova; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

2.  Intrathecal sICAM-1 production in multiple sclerosis--correlation with triple dose Gd-DTPA MRI enhancement and IgG index.

Authors:  Göksemin Acar; Fethi Idiman; Güldal Kirkali; Serkan Ozakbaş; Gülgün Oktay; Handan Cakmakçi; Egemen Idiman
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

3.  Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?

Authors:  A Salmaggi; A Dufour; M Eoli; E Corsini; L La Mantia; G Massa; A Nespolo; C Milanese
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

Review 4.  Multiple sclerosis therapy. A practical guide.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

5.  Is MS an inflammatory or primary degenerative disease?

Authors:  Jacek Losy
Journal:  J Neural Transm (Vienna)       Date:  2013-09-06       Impact factor: 3.575

6.  Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a.

Authors:  Shlomo Flechter; Tirza Klein; Lea Pollak
Journal:  Neurol Int       Date:  2011-06-15

7.  The effects of high dose interferon-β1a on plasma microparticles: correlation with MRI parameters.

Authors:  Mary Lowery-Nordberg; Erin Eaton; Eduardo Gonzalez-Toledo; Meghan K Harris; Kathrine Chalamidas; Jeanie McGee-Brown; Chaitanya V Ganta; Alireza Minagar; David Cousineau; J Steven Alexander
Journal:  J Neuroinflammation       Date:  2011-05-09       Impact factor: 8.322

8.  Link between neurodegeneration and trabecular meshwork injury in glaucomatous patients.

Authors:  Yong Zhang; Qinmei Yang; Feng Guo; Xia Chen; Lin Xie
Journal:  BMC Ophthalmol       Date:  2017-11-28       Impact factor: 2.209

Review 9.  Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence.

Authors:  Souhel Najjar; Daniel M Pearlman; Orrin Devinsky; Amanda Najjar; David Zagzag
Journal:  J Neuroinflammation       Date:  2013-12-01       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.